The synergy of RayBiotech’s innovative portfolio with SeraCare’s global reach and expertise in virology, serology, immunology and molecular biology supports the acceleration of biomedical research and product development, the two companies said.
Susan Vogt, president and CEO of SeraCare Life Sciences, said: “The partnership with RayBiotech directly supports SeraCare’s growth strategy by expanding our offering of value-added proteomic tools to life sciences researchers around the world. RayBiotech is well regarded in the field of proteomics and their innovative products will benefit our client base while our mutual commitment to science and medicine offers opportunity for clinical advancements.”
Ray Huang, president of RayBiotech, said: “By adding SeraCare Life Sciences as an agent, we hope to achieve both increased demand for RayBiotech products in clinical and diagnostic markets and fuel increased opportunity for biomarker discovery and validation.”